This animated video visually explores the distinct mechanisms of action (MOAs) of anticholinergics and VMAT-2 inhibitors in managing tardive dyskinesia.
Supported by an educational grant from Neurocrine Biosciences, Inc.
Kevin Williams, MS, MPAS, PA-C, details how clinicians can more closely incorporate caregivers into patient treatment plans, as well as how to navigate a conversation with a patient who has stopped taking their medications for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses how providers can reassess treatment plans should tardive dyskinesia (TD) develop and what practices can be incorporated to identify mild, moderate, and severe TD.
Amber Hoberg, MSN, APRN, PMHNP-BC, discussed why tardive dyskinesia (TD) continues to be underdiagnosed and what screening tools should be used to identify and diagnose the disorder with patient needs in mind.